Výsledky vyhledávání

Akademický článek

Chronic disease IMPACT (chronic disease early detection and improved management in primary care project): An Australian stepped wedge cluster randomised trial.

Autor: Jones JL; Nephrology, Western Health, Melbourne, Australia.; Western Health Chronic Disease Alliance, Melbourne, Australia.; Department of Medicine, The University of Melbourne, Melbourne, Australia., Simons K; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia.; Office for Research, Western Health, Melbourne, Australia., Manski-Nankervis JA; Department of General Practice, The University of Melbourne, Melbourne, Australia., Lumsden NG; Nephrology, Western Health, Melbourne, Australia.; Western Health Chronic Disease Alliance, Melbourne, Australia.; Department of General Practice, The University of Melbourne, Melbourne, Australia., Fernando S; Nephrology, Western Health, Melbourne, Australia., de Courten MP; Mitchell Institute for Education and Health Policy, Melbourne, Australia.; Centre for Chronic Disease, Victoria University, Melbourne, Australia., Cox N; Western Health Chronic Disease Alliance, Melbourne, Australia.; Centre for Chronic Disease, Victoria University, Melbourne, Australia.; Cardiology, Western Health, Melbourne, Australia., Hamblin PS; Western Health Chronic Disease Alliance, Melbourne, Australia.; Department of Medicine, The University of Melbourne, Melbourne, Australia.; Endocrinology and Diabetes, Western Health, Melbourne, Australia., Janus ED; Western Health Chronic Disease Alliance, Melbourne, Australia.; Department of Medicine, The University of Melbourne, Melbourne, Australia.; Medicine, Western Health, Melbourne, Australia., Nelson CL; Nephrology, Western Health, Melbourne, Australia.; Western Health Chronic Disease Alliance, Melbourne, Australia.; Department of Medicine, The University of Melbourne, Melbourne, Australia.

Publikováno v: Digital health [Digit Health] 2023 Aug 14; Vol. 9, pp. 20552076231194948. Date of Electronic Publication: 2023 Aug 14 (Print Publication: 2023).

Zobrazit plný text záznamu

Akademický článek

Using electronic medical record data to assess chronic kidney disease, type 2 diabetes and cardiovascular disease testing, recognition and management as documented in Australian general practice: a cross-sectional analysis.

Autor: Jones JL; Nephrology, Western Health, Melbourne, Victoria, Australia Julia.Jones@wh.org.au.; Medicine, University of Melbourne, Melbourne, Victoria, Australia.; Western Health Chronic Disease Alliance, Melbourne, Victoria, Australia., Lumsden NG; Nephrology, Western Health, Melbourne, Victoria, Australia.; Western Health Chronic Disease Alliance, Melbourne, Victoria, Australia.; General Practice, University of Melbourne, Melbourne, Victoria, Australia., Simons K; Western Health Chronic Disease Alliance, Melbourne, Victoria, Australia.; Epidemiology and Biostatistics, University of Melbourne, Melbourne, Victoria, Australia., Ta'eed A; Nephrology, Western Health, Melbourne, Victoria, Australia., de Courten MP; Mitchell Institute for Education and Health Policy, Melbourne, Victoria, Australia.; Chronic Disease Prevention and Management, Victoria University, Melbourne, Victoria, 3011., Wijeratne T; Western Health Chronic Disease Alliance, Melbourne, Victoria, Australia.; La Trobe University, Melbourne, Victoria, Australia.; Neurology, Western Health, Melbourne, Victoria, Australia., Cox N; Medicine, University of Melbourne, Melbourne, Victoria, Australia.; Western Health Chronic Disease Alliance, Melbourne, Victoria, Australia.; Cardiology, Western Health, Melbourne, Victoria, Australia., Neil CJA; Medicine, University of Melbourne, Melbourne, Victoria, Australia.; Western Health Chronic Disease Alliance, Melbourne, Victoria, Australia.; Cardiology, Western Health, Melbourne, Victoria, Australia., Manski-Nankervis JA; General Practice, University of Melbourne, Melbourne, Victoria, Australia., Hamblin PS; Medicine, University of Melbourne, Melbourne, Victoria, Australia.; Western Health Chronic Disease Alliance, Melbourne, Victoria, Australia.; Endocrinology and Diabetes, Western Health, Melbourne, Victoria, Australia., Janus ED; Medicine, University of Melbourne, Melbourne, Victoria, Australia.; Western Health Chronic Disease Alliance, Melbourne, Victoria, Australia.; Medicine, Western Health, Melbourne, Victoria, Australia., Nelson CL; Nephrology, Western Health, Melbourne, Victoria, Australia.; Medicine, University of Melbourne, Melbourne, Victoria, Australia.; Western Health Chronic Disease Alliance, Melbourne, Victoria, Australia.

Publikováno v: Family medicine and community health [Fam Med Community Health] 2022 Feb; Vol. 10 (1).

Zobrazit plný text záznamu

Akademický článek

High intraluminal pressure promotes vascular inflammation via caveolin-1.

Autor: Michell DL; Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.; Department of Medicine, Monash University, Clayton, VIC, Australia., Shihata WA; Baker Heart and Diabetes Institute, Melbourne, VIC, Australia. waled.shihata@baker.edu.au.; Department of Medicine, Monash University, Clayton, VIC, Australia. waled.shihata@baker.edu.au.; Cardiovascular Disease Program, Biomedicine Discovery Institute, Monash University, Clayton, Australia. waled.shihata@baker.edu.au., Andrews KL; Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.; Cardiovascular Disease Program, Biomedicine Discovery Institute, Monash University, Clayton, Australia.; Department of Pharmacology, Monash University, Clayton, VIC, Australia., Abidin NAZ; Cardiovascular Disease Program, Biomedicine Discovery Institute, Monash University, Clayton, Australia.; Department of Pharmacology, Monash University, Clayton, VIC, Australia., Jefferis AM; Department of Pharmacology, Monash University, Clayton, VIC, Australia., Sampson AK; Baker Heart and Diabetes Institute, Melbourne, VIC, Australia., Lumsden NG; Baker Heart and Diabetes Institute, Melbourne, VIC, Australia., Huet O; Baker Heart and Diabetes Institute, Melbourne, VIC, Australia., Parat MO; School of Pharmacy, University of Queensland, St Lucia, QLD, Australia., Jennings GL; Baker Heart and Diabetes Institute, Melbourne, VIC, Australia., Parton RG; Institute for Molecular Bioscience and Centre for Microscopy and Microanalysis, University of Queensland, St Lucia, QLD, Australia., Woollard KJ; Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, UK., Kaye DM; Baker Heart and Diabetes Institute, Melbourne, VIC, Australia., Chin-Dusting JPF; Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.; Department of Medicine, Monash University, Clayton, VIC, Australia.; Cardiovascular Disease Program, Biomedicine Discovery Institute, Monash University, Clayton, Australia.; Department of Pharmacology, Monash University, Clayton, VIC, Australia., Murphy AJ; Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.

Publikováno v: Scientific reports [Sci Rep] 2021 Mar 15; Vol. 11 (1), pp. 5894. Date of Electronic Publication: 2021 Mar 15.

Zobrazit plný text záznamu

Akademický článek

Nitroxyl (HNO) reduces endothelial and monocyte activation and promotes M2 macrophage polarization.

Autor: Andrews KL; Vascular Pharmacology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia Cardiovascular Disease Program and Department of Pharmacology, Biomedical Discovery Institute, Monash University, Clayton, Victoria 3800, Australia karen.andrews@monash.edu., Sampson AK; Vascular Pharmacology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia., Irvine JC; Vascular Pharmacology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia., Shihata WA; Vascular Pharmacology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia Cardiovascular Disease Program and Department of Pharmacology, Biomedical Discovery Institute, Monash University, Clayton, Victoria 3800, Australia., Michell DL; Vascular Pharmacology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia., Lumsden NG; Vascular Pharmacology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia., Lim C; Vascular Pharmacology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia., Huet O; Vascular Pharmacology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia., Drummond GR; Cardiovascular Disease Program and Department of Pharmacology, Biomedical Discovery Institute, Monash University, Clayton, Victoria 3800, Australia., Kemp-Harper BK; Cardiovascular Disease Program and Department of Pharmacology, Biomedical Discovery Institute, Monash University, Clayton, Victoria 3800, Australia., Chin-Dusting JP; Vascular Pharmacology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia Cardiovascular Disease Program and Department of Pharmacology, Biomedical Discovery Institute, Monash University, Clayton, Victoria 3800, Australia.

Publikováno v: Clinical science (London, England : 1979) [Clin Sci (Lond)] 2016 Sep 01; Vol. 130 (18), pp. 1629-40. Date of Electronic Publication: 2016 May 26.

Zobrazit plný text záznamu

Akademický článek

Nitroxyl: a vasodilator of human vessels that is not susceptible to tolerance.

Autor: Andrews KL; Vascular Pharmacology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia., Lumsden NG; Vascular Pharmacology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia., Farry J; Vascular Pharmacology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia., Jefferis AM; Vascular Pharmacology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia., Kemp-Harper BK; †Vascular Biology and Immunopharmacology Group, Department of Pharmacology, Monash University, Clayton, Victoria 3800, Australia., Chin-Dusting JP; Vascular Pharmacology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia.

Publikováno v: Clinical science (London, England : 1979) [Clin Sci (Lond)] 2015 Jul; Vol. 129 (2), pp. 179-87.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání